



*Wageningen, April 16, 2007*

## **Keygene expands its Genome Analysis Platform with the Illumina Genome Analyzer and the Roche Genome Sequencer FLX system**

Keygene is pleased to announce that it expanded its technology platform with the **Roche Genome Sequencer FLX system**, an upgrade of its Roche GS20 system, and the acquisition of the **Illumina®** Genome Analyzer. With both new generation high throughput sequencing platforms at hand, Keygene will be able to further develop its array of innovative DNA sequence-based applications and provide a broader range of services to its customers.

Roche and Keygene already entered into a co-marketing agreement to promote the new applications that Keygene developed with their next generation sequencing platforms.

After building experience for almost two years on the GS20 system, Keygene will now be able to transfer its technological and bioinformatics experience to the higher throughput GS FLX system. Due to the flexible set-up of the GS FLX system Keygene is now better equipped to accommodate the specific needs of its customers with sequencing services and applications, such as CRoPS™ (for polymorphism discovery), KeyPoint™ (for mutation screening) and transposon display in a service mode. The Illumina sequence technology adds another dimension to the sequence capacity of Keygene allowing for the development of other applications, like sequence-based AFLP® genotyping, whole genome physical mapping and cDNA-AFLP based transcript profiling.

'These new, cutting edge sequencing platforms complement each other in their applications and will allow us to move fast forward in molecular genetic analysis and improvement of crops and as such support the realization of our vision on molecular breeding using High Throughput Sequencing', says Anker Sørensen, acting head of Applied Research.

Mark van Haaren, manager Business Development of Keygene states: 'with the new set of equipments and the developed proprietary applications Keygene is well positioned to serve a broad range of customers with needs that range from straight forward BAC and genome sequencing up to sequence-based analysis of complex biological traits'.

### **About Keygene**

*Keygene N.V. ([www.keygene.com](http://www.keygene.com)) is a R&D company with the mission to be the leading company in developing and applying DNA expertise in the field of molecular genetics for its shareholder breeding companies. Keygene has developed a strong proprietary technology platform based on AFLP®, a DNA marker technology for genome analysis, transcript profiling and genetic analysis. For diagnostic purposes, SNPWave™, a multiplexed SNP detection technology was developed. New sequencing based technologies include CRoPS™ and KeyPoint™. Keygene exploits its proprietary technologies, databases and know-how through contract research and products for applications in the Life Sciences industry and more specifically in innovative breeding applications such as Breeding by Design®. Keygene has five shareholders consisting of major vegetable seed companies that collaborate in the BioSeeds strategic alliance: De Ruiter Seeds, ENZA Zaden, Rijk Zwaan, Vilmorin & Cie and Takii & Co. Keygene has around 100 researchers and staff.*

### **For more information please contact:**

Keygene N.V.: Dr. Mark J.J. van Haaren, +31 317 466866, [mark.van-haaren@keygene.com](mailto:mark.van-haaren@keygene.com)